Series C+

Peregrine Technologies' appointment of Adrian Kaplan isn't just a new hire; it's a calculated move to mature its financial operations for global scale.

With $9M in new funding, Trellis Bioscience advances a novel antibody that shatters bacterial defenses, offering hope for devastating joint infections.

With a $70M Series C and unique 3D printing tech, SWISSto12 proves the new space economy is moving beyond hype to sustainable, profitable infrastructure.

Emergent's massive Series C and unicorn status signal a new frontier for SMBs. But can its "agentic AI" truly deliver production-ready software, or do hidden costs and technical risks remain?

With a fresh $46M Series C, Quadric's programmable chips aim to free emerging markets from hyperscaler costs, fueling a new wave of on-device intelligence.

Liquid Instruments' GenInst Studio uses AI to build custom test gear from text prompts, slashing R&D time from months to minutes and challenging industry giants.

With new leaders from Coinbase and Adyen, Cardless is leveraging its $60M war chest to move beyond credit and build an AI-powered 'financial OS' for any brand.

With €33M in fresh capital, Cyllene Therapeutics is advancing a novel gene therapy for bladder disease. We analyze the tech, the investors, and the plan.

With a $76M Series C led by SBI Holdings, EDX Markets is scaling its institutional-grade crypto infrastructure, aiming to merge Wall Street's rigor with digital innovation.

With €33M in new funding, Cyllene Therapeutics is advancing a novel gene therapy using HSV-1 vectors. Could this be the one-shot cure for millions?

With an $85M insider-led round and a seasoned M&A expert as CEO, Flare Therapeutics sharpens its focus on a novel prostate cancer drug, FX-111.

Eckuity Capital launches Fund II, leading a Series C in Automata Technologies with Danaher, signaling a major push to commercialize AI in life science labs.

Lycia Therapeutics' oversubscribed $75M Series D validates its unique LYTAC platform, which aims to treat autoimmune diseases by destroying harmful proteins.

Goldman Sachs leads a major investment in Taktile, betting that specialized 'Agentic AI' is the key to unlocking real value in the regulated financial sector.

Taktile secures a massive Goldman Sachs-led investment to embed AI agents in banking's core. Is this the tipping point for autonomous financial decisions?

Australian radiopharma innovator AdvanCell is planting its flag in Greater Boston with a new HQ and factory, a strategic move to scale its potent Lead-212 therapy.

The dream of the online side-hustle is burning out Australia's solo entrepreneurs. Can a new wave of AI assistants and a 'no app tax' model restore balance?

After conquering football, Scorability is expanding to seven new sports, leveraging AI and "mentality assessments" to change how colleges find talent.

A breakthrough 'pap smear for the pancreas' that detects early cancer has secured major funding, offering new hope against one of the deadliest diseases.

With a new $75M, Boston Metal scales its MOE tech to produce clean, critical metals from waste, aiming to secure supply chains and decarbonize industry.